Ensysce Biosciences is committed to finding a solution to the opioid crisis plaguing the US and other developed countries around the world. Through its proprietary TAAP technology Ensysce is in the process of receiving approval for an abuse-resistant yet still pain-relieving opioid. The company released its quarterly report for 1Q2024, which again shows the great progress the company is making in moving toward its goal of providing a much-needed opioid alternative.